If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
== Metallurgy == In metallurgy, gas flushing removes dissolved gases from the molten metal prior to the material being processed. For example, before casting aluminium alloys, argon bubbles are injected into liquid aluminium using a rotary degasser. The argon bubbles rise to the surface, bringing with them some of the dissolved hydrogen. The degassing step reduces the occurrence of hydrogen gas porosity. In the steel making process, this method is used very commonly for duplex steel and some high reactivity metals.
=== The name === The word Pseudomonas means false unit, being derived from the Greek words pseudēs (Greek: ψευδής – false) and monas (Latin: monas, from Greek: μονάς – a single unit). The word was used early in the history of microbiology to refer to germs. The specific name fluorescens refers to the microbe's secretion of a soluble fluorescent pigment called pyoverdin, which is a type of siderophore.
== Epidemiology == Donohue syndrome is an extremely rare disorder that occurs in one of every million births worldwide. Several dozen cases have been reported in the medical community, and in the reported cases of the disorder, it has been found that the females are twice as likely to have the disorder as men.
=== Metabolism === The metabolism of progesterone is rapid and extensive, and it occurs mainly in the liver, though enzymes that metabolize progesterone are also expressed widely in the brain, skin, and various other extrahepatic tissues. Progesterone has an elimination half-life of only approximately five minutes in circulation. The metabolism of progesterone is complex, and it may form as many as 35 different unconjugated metabolites when it is ingested orally. Progesterone is highly susceptible to enzymatic reduction via reductases and hydroxysteroid dehydrogenases because of its double bond (between the C4 and C5 positions) and its two ketones (at the C3 and C20 positions). The major metabolic pathway of progesterone is reduction by 5α-reductase and 5β-reductase, into the dihydrogenated 5α-dihydroprogesterone and 5β-dihydroprogesterone, respectively. This is followed by the further reduction of these metabolites via 3α-hydroxysteroid dehydrogenase and 3β-hydroxysteroid dehydrogenase into the tetrahydrogenated allopregnanolone, pregnanolone, isopregnanolone, and epipregnanolone. Subsequently, 20α-hydroxysteroid dehydrogenase and 20β-hydroxysteroid dehydrogenase reduce these metabolites to form the corresponding hexahydrogenated pregnanediols (eight different isomers in total), which are then conjugated via glucuronidation and/or sulfation, released from the liver into circulation, and excreted by the kidneys into the urine.
Sources: en.wikipedia.org
== Medicines == Treatments based on monoclonal antibodies have been produced related to CGRP or CGRP receptors. They have been shown to be effective in patients who experience migraine headaches, both with and without aura, and both episodic and chronic cluster headache. These are the first class of preventive medications originally designed and approved for people with migraine. Due to the nature of the monoclonal antibodies, they must be administered parenterally, preferably by injection. The first CGRP related medication approved by the FDA is called erenumab (trade name Aimovig), produced by pharmaceutical company Amgen and Novartis. It interacts with the CGRP receptor. It is injected once monthly with a dose of 70 or 140 mg. Few adverse effects were reported (most related to injection site reactions) and patients had a significant reduction in migraines. The second approved by the FDA is fremanezumab (trade name Ajovy), produced by the Teva Pharmaceuticals company. It interacts with the CGRP protein, whose expression is related to migraine attacks. It may be administered monthly or every three months, giving options for users. Trials have shown a reduction of greater than 50% of migraine days for those who responded. There were few significant side effects during trials, most related to injection site reactions. The third CGRP medication approved by the FDA is galcanezumab (trade name Emgality), produced by the Eli Lilly and Company. It interacts with the CGRP protein, whose expression is related to migraine attacks.
=== 2018–2021: Dancing on Ice and Diva === In January 2018, Collins appeared on Celebrity 100% Hotter in an attempt to change her style. Collins admitted she was "terrified" about having a makeover but said she was keen to try out some different trends. In February 2018, she took part in the fourth series of Celebs Go Dating. During her time on the show, Collins walked out on one of her dates within the first few minutes after he branded her a "diva" due to her being late, whilst she was also reprimanded by the dating experts after she failed to turn up to her date with Laurence, who was planning to take her to Paris. In June 2018, she released her second book, titled The GC: How to Be a Diva, in which she provides advice and self help for women to gain confidence. In an interview on Loose Women, she admitted to using a ghostwriter. She also guest starred in a promotional advert for Netflix's Orange Is the New Black. Collins went on to appear in Gemma Collins: Diva España, a one-off reality television special which aired in August 2018. In September 2018, Collins took part in the thirteenth series of Celebrity MasterChef. She was eliminated in the second round of the third heat after her sea bass served in greaseproof paper failed to impress the judges. In November 2018, Collins was the subject of a song released by Tallia Storm, titled "It's the GC (Diva Forever)". The song was featured in one of Collins' clothing advertisements for Boohoo.com and later became the theme song of her television franchise Gemma Collins: Diva.
Gabapentin, sold under the brand name Neurontin among others, is an anticonvulsant medication used to treat neuropathic pain (postherpetic neuralgia) and partial seizures of epilepsy. Gabapentin is a central nervous system (CNS) depressant and derivative of the inhibitory neurotransmitter, GABA. It is used for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain. It is moderately effective: about 30–40% of those given gabapentin for diabetic neuropathy or postherpetic neuralgia have a meaningful benefit. Gabapentin binds to α2δ subunits to modulate calcium channel function and neurotransmitter release, weakly affects glutamate signaling pathways, and does not act on GABA receptors. Sleepiness and dizziness are the most common side effects. Serious side effects include extreme sedation, respiratory depression and allergic reactions. In December 2008, the US Food and Drug Administration issued a class-wide warning for gabapentinoids for an increased risk of suicide. Approximately two years after this pronouncement, a pharmacoepidemiologic study was conducted that showed there was no outstanding difference in suicide attempt rates between pre- and post-gabapentin prescription groups. Gabapentin was first approved for use in the United Kingdom in 1993. It has been available as a generic medication in the United States since 2004. It is the first of several other drugs that are similar in structure and mechanism, called gabapentinoids.
== Further reading == Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. (October 2023). "Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis". The New England Journal of Medicine. 389 (17): 1579–1589. doi:10.1056/NEJMoa2301333. hdl:1854/LU-01JMVNTYQXH55FHHB47BSMETXX. PMID 37888917. Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA, et al. (August 2024). "Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials". Lancet. 404 (10451): 445–460. doi:10.1016/S0140-6736(24)01203-0. PMID 39067461.
In that same war there was opposition from Bolivians, especially in Chuquisaca to preserve their privileges, when mentioning that the confederate project favored Peru to the detriment of Bolivia by creating 2 Peruvian states (Republic of North Peru and Republic of South Peru) that would generate a disadvantage in decisions by having the Bolivian state 1 vote of 3 (there being a general opposition to what was agreed in the Tacna Congress), Bolivians were already discontent since Santa Cruz had settled in Lima, when he was expected to rule from Bolivian Republic, so he was accused of being a Peruvianphile. Therefore, both the Bolivian opposition to Santa Cruz, as well as the Bolivian defense of the confederation against Agustín Gamarra, was nourished by anti-Peruvianism. In addition, before, during and after the War of the Pacific, discourses emerged (especially in liberal groups) with anti-militarist, anti-oligarchic, anti-caudillo and anti-Peruvian tendencies, while antimilitarism was related to anti-Peruvianism. While the "guerristas" sought to continue the war and honour the alliance with Peru, the Bolivian conservatives or pacifists sought to achieve a peace agreement with Chile as soon as possible, even if to do so they had to rant against the Peruvians. Justiniano Sotomayor Guzmán's proposal in his letters to Hilarión Daza that "Bolivia has no better friend than Chile, nor worse executioner than Peru." Later, as Paz Soldán recalls, Bolivia (already an ally of Peru since 1873) tried to dispose of Arica and Pisagua, signing treaties with Brazil in 1878.
Sources: en.wikipedia.org
=== Blood thinners === The trend in skin surgery over the last 10 years has been to continue anticoagulants while performing skin surgery. Most cutaneous bleeding can be controlled with electrocautery, especially bipolar forceps. The benefit gained by ease of hemostasis is weighed against the risk of stopping anticoagulants; and it is generally preferred to continue anticoagulants.
=== Storage === In the event that an object is removed from an exhibition, for treatment, or transportation careful examination of the state of the textile is required for best practice conservation records, accession records, and curatorial notes. The various materials and techniques discussed above should be employed, as well as careful consideration of humidity, light, and pollution that may be a threat during transport and handling.
=== Diabetes === In contrast to previous studies, a recent study of streptozotocin-induced and high-fat diet-induced murine models of diabetes found that the FFAR3-activating drug, AR420626, increased blood plasma insulin levels and stimulated skeletal muscle to take up glucose and thereby improved glucose tolerance test results. Other recent studies have reported that activated FFAR3 may reduce, increase, or have little effect on insulin secretion depending on 1) the levels of ambient glucose and FFAR3 activators studied, (2) human or animal species studied, (3) age of the animals studied, and (4) variations in the proportions of alpha, beta, and delta cells in the pancreatic islets of humans. The role of FFAR3 in human as well as animal models of insulin secretion and diabetes requires further studies.
The mechanism of the change in pore size is simple, the pores are smaller under LCST due to the elongated chains of PNIPAAm within the pores, as temperature increases to and above LCST, the chains retract into a globular formation increasing the pore size.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.